

Edgar Filing: Worden Andrew Barron - Form SC 13D/A

Worden Andrew Barron
Form SC 13D/A
December 29, 2009

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

SCHEDULE 13D/A
Under the Securities Exchange Act of 1934
(Amendment No 2)

Biostar Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

090678103

(CUSIP Number)

Rebecca Baum

730 FIFTH AVENUE, 25TH FLOOR

NEW YORK, NY 10019

212-359-0204

(Name, Address and Telephone Number of Person Authorized to Receive Notices
and Communications)

December 16, 2009

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of 240.13d1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. [] Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See 240.13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP 090678103

13D/A

1 Name of Reporting Person
Andrew Barron Worden
I.R.S. Identification No. of Above Person

2 Check the Appropriate Box if a Member of a Group (a) []
(b) []

3 SEC Use Only

4 Source of Funds
PF

5 Check Box if Disclosure of Legal Proceedings is Required Pursuant to
Items 2(d) or 2(e)
[]

6 Citizenship or Place of Organization
United States

Number of 7 Sole Voting Power
Shares
Owned 266,938 shares

By Each 8 Shared Voting Power

Edgar Filing: Worden Andrew Barron - Form SC 13D/A

Reporting Person With	540,907 shares
9	Sole Dispositive Power 266,938 shares
10	Shared Dispositive Power 2,166,248 shares
11	Aggregate Amount Beneficially Owned by Each Reporting Person 2,433,336 shares
12	Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares []
13	Percent of Class Represented by Amount in Row (11) 9.9%
14	Type of Reporting Person IN

Item 1. Security and Issuer.

This statement relates to shares of common stock, par value \$0.001 per share, (the "Common Stock") of Biostar Pharmaceuticals, Inc. a Maryland corporation (the "Company") having its principal executive offices at No. 588 Shiji Avenue, Xiangyang City, Shaanxi Province, The People's Republic of China.

Item 2. Identity and Background.

This Statement is filed by Andrew Barron Worden, an individual (the "Reporting Person"), whose residence address is 50 Central Park South, Unit 34/35 New York, NY 10019. Andrew Barron Worden is the Managing Partner of Barron Capital Advisors LLC, a Delaware Limited Liability Company which is the General Partner to Barron Partners LP, a Delaware Limited Partnership, whose principal business is investing.

During the last five years, to the best knowledge of the Reporting Person, neither the Reporting Person nor any controlling person of the Reporting Person has (i) been convicted in a criminal proceeding, or (ii) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or State securities laws or finding any violation with respect to such laws.

Item 3. Source and Amount of Funds or Other Consideration.

All purchases of the Common Stock of the Company were made using personal funds.

Item 4. Purpose of Transaction.

All Issuer's securities owned by the Reporting Person have been acquired by the Reporting Person for investment purposes only.

1	Name of Reporting Person Barron Partners LP I.R.S. Identification No. of Above Person 43-1981699
2	Check the Appropriate Box if a Member of a Group (a) [] (b) []
3	SEC Use Only
4	Source of Funds WC
5	Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) []
6	Citizenship or Place of Organization Delaware
Number of Shares Owned By Each	7 Sole Voting Power 540,907 shares
	8 Shared Voting Power

Edgar Filing: Worden Andrew Barron - Form SC 13D/A

Reporting Person With 0
9 Sole Dispositive Power
540,907 shares
10 Shared Dispositive Power
0
11 Aggregate Amount Beneficially Owned by Each Reporting Person
540,907 shares
12 Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares
[]
13 Percent of Class Represented by Amount in Row (11)
2.2%
14 Type of Reporting Person
PN

Item 1. Security and Issuer.

This statement relates to shares of common stock, par value \$0.001 per share, (the "Common Stock") of Biostar Pharmaceuticals, Inc. a Maryland corporation (the "Company") having its principal executive offices at No. 588 Shiji Avenue, Xiangyang City, Shaanxi Province, The People's Republic of China.

Item 2. Identity and Background.

This Statement is filed by Barron Partners LP, a Delaware Limited Partnership (the "Reporting Person"), whose business address is 730 Fifth Avenue, 25th Floor, New York, NY 10019. The Reporting Person is principally engaged in making investments.

The General Partner of the Reporting Person is Barron Capital Advisors LLC, a Delaware Limited Liability Company, (the "General Partner"). Andrew B. Worden is the managing member of the General Partner.

During the last five years, to the best knowledge of the Reporting Person, neither the Reporting Person nor any controlling person of the Reporting Person has (i) been convicted in a criminal proceeding, or (ii) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or State securities laws or finding any violation with respect to such laws.

Item 3. Source and Amount of Funds or Other Consideration.

All purchases of the Common Stock of the Company were made using working capital.

Item 4. Purpose of Transaction.

All Issuer's securities owned by the Reporting Person have been acquired by the Reporting Person for investment purposes only.

1 Name of Reporting Person
Golden1177 LP
I.R.S. Identification No. of Above Person
2 Check the Appropriate Box if a Member of a Group (a) []
(b) []
3 SEC Use Only
4 Source of Funds
WC
5 Check Box if Disclosure of Legal Proceedings is Required Pursuant to
Items 2(d) or 2(e)
[]
6 Citizenship or Place of Organization
Delaware
Number of Shares 7 Sole Voting Power

Edgar Filing: Worden Andrew Barron - Form SC 13D/A

Owned		865,091 shares	
By Each	8		Shared Voting Power
Reporting Person With		0	
	9		Sole Dispositive Power
		0	
10			Shared Dispositive Power
			865,091 shares
11			Aggregate Amount Beneficially Owned by Each Reporting Person
			865,091 shares
12			Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares
			[]
13			Percent of Class Represented by Amount in Row (11)
			3.5%
14			Type of Reporting Person
			PN

Item 1. Security and Issuer.

This statement relates to shares of common stock, par value \$0.001 per share, (the "Common Stock") of Biostar Pharmaceuticals, Inc. a Maryland corporation (the "Company") having its principal executive offices at No. 588 Shiji Avenue, Xiangyang City, Shaanxi Province, The People's Republic of China.

Item 2. Identity and Background.

This Statement is filed by Golden1177 LP, a Delaware Limited Partnership (the "Reporting Person"), whose business address is #500-1177 West Hastings Street, Vancouver BC V6E 2K3 Canada. The Reporting Person is principally engaged in making investments.

The General Partner of the Reporting Person is Golden Properties, Ltd (the "General Partner"). Alex Lau is the Director of the General Partner.

The Reporting Person has granted trading authorization of the shares of Common Stock to Andrew Barron Worden and shares dispositive power of the shares of Common Stock with Andrew Barron Worden.

During the last five years, to the best knowledge of the Reporting Person, neither the Reporting Person nor any controlling person of the Reporting Person has (i) been convicted in a criminal proceeding, or (ii) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or State securities laws or finding any violation with respect to such laws.

Item 3. Source and Amount of Funds or Other Consideration.

All purchases of the Common Stock of the Company were made using working capital.

Item 4. Purpose of Transaction.

All Issuer's securities owned by the Reporting Person have been acquired by the Reporting Person for investment purposes only.

1	Name of Reporting Person	XWRT2 LP
	I.R.S. Identification No. of Above Person	
2	Check the Appropriate Box if a Member of a Group (a) []	
	(b) []	
3	SEC Use Only	
4	Source of Funds	WC
5	Check Box if Disclosure of Legal Proceedings is Required Pursuant to	
	Items 2(d) or 2(e)	
	[]	
6	Citizenship or Place of Organization	Delaware

Edgar Filing: Worden Andrew Barron - Form SC 13D/A

Number of Shares Owned	7	Sole Voting Power
By Each Reporting Person With	8	Shared Voting Power
		0
	9	Sole Dispositive Power
		0
10		Shared Dispositive Power 69,290 shares
11		Aggregate Amount Beneficially Owned by Each Reporting Person 69,290 shares
12		Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares []
13		Percent of Class Represented by Amount in Row (11) 0.3%
14		Type of Reporting Person PN

Item 1. Security and Issuer.

This statement relates to shares of common stock, par value \$0.001 per share, (the "Common Stock") of Biostar Pharmaceuticals, Inc. a Maryland corporation (the "Company") having its principal executive offices at No. 588 Shiji Avenue, Xiangyang City, Shaanxi Province, The People's Republic of China.

Item 2. Identity and Background.

This Statement is filed by XWRT2 LP, a Delaware Limited Partnership (the "Reporting Person"), whose business address is 131 Laurel Grove Avenue Kentfield, CA 94904. The Reporting Person is principally engaged in making investments.

The General Partner of the Reporting Person is Joseph Abrams (the "General Partner"), an individual.

The Reporting Person has granted trading authorization of the shares of Common Stock to Andrew Barron Worden and shares dispositive power of the shares of Common Stock with Andrew Barron Worden.

During the last five years, to the best knowledge of the Reporting Person, neither the Reporting Person nor any controlling person of the Reporting Person has (i) been convicted in a criminal proceeding, or (ii) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or State securities laws or finding any violation with respect to such laws.

Item 3. Source and Amount of Funds or Other Consideration.

All purchases of the Common Stock of the Company were made using working capital.

Item 4. Purpose of Transaction.

All Issuer's securities owned by the Reporting Person have been acquired by the Reporting Person for investment purposes only.

1	Name of Reporting Person SBMT2 LP I.R.S. Identification No. of Above Person
2	Check the Appropriate Box if a Member of a Group (a) [] (b) []
3	SEC Use Only
4	Source of Funds WC
5	Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) []

Edgar Filing: Worden Andrew Barron - Form SC 13D/A

6 Citizenship or Place of Organization
 Delaware

Number of 7 Sole Voting Power
 Shares
 Owned 46,833 shares

By Each 8 Shared Voting Power
 Reporting 0
 Person With

 9 Sole Dispositive Power
 0

10 Shared Dispositive Power
 46,833 shares

11 Aggregate Amount Beneficially Owned by Each Reporting Person
 46,833 shares

12 Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares
 []]

13 Percent of Class Represented by Amount in Row (11)
 0.2%

14 Type of Reporting Person
 PN

Item 1. Security and Issuer.

This statement relates to shares of common stock, par value \$0.001 per share, (the "Common Stock") of Biostar Pharmaceuticals, Inc. a Maryland corporation (the "Company") having its principal executive offices at No. 588 Shiji Avenue, Xiangyang City, Shaanxi Province, The People's Republic of China.

Item 2. Identity and Background.

This Statement is filed by SBMT2 LP, a Delaware Limited Partnership (the "Reporting Person"), whose business address is 104 S. Pecos Street Midland, TX 79701. The Reporting Person is principally engaged in making investments.

The General Partner of the Reporting Person is Carlton Beal Family Trust FBO Spencer Beal (the "General Partner"). Spencer Beal, an individual is the Trustee to the General Partner.

The Reporting Person has granted trading authorization of the shares of Common Stock to Andrew Barron Worden and shares dispositive power of the shares of Common Stock with Andrew Barron Worden.

During the last five years, to the best knowledge of the Reporting Person, neither the Reporting Person nor any controlling person of the Reporting Person has (i) been convicted in a criminal proceeding, or (ii) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or State securities laws or finding any violation with respect to such laws.

Item 3. Source and Amount of Funds or Other Consideration.

All purchases of the Common Stock of the Company were made using working capital.

Item 4. Purpose of Transaction.

All Issuer's securities owned by the Reporting Person have been acquired by the Reporting Person for investment purposes only.

1 Name of Reporting Person
 Godfrey2468 LP
 I.R.S. Identification No. of Above Person

2 Check the Appropriate Box if a Member of a Group (a) []
 (b) []]

3 SEC Use Only

4 Source of Funds
 WC

Edgar Filing: Worden Andrew Barron - Form SC 13D/A

5 Check Box if Disclosure of Legal Proceedings is Required Pursuant to
Items 2(d) or 2(e)

[]

6 Citizenship or Place of Organization

Delaware

Number of Shares Owned 7 Sole Voting Power

58,694 shares

By Each 8 Shared Voting Power

Reporting Person With 0

9 Sole Dispositive Power

0

10 Shared Dispositive Power

58,694 shares

11 Aggregate Amount Beneficially Owned by Each Reporting Person

58,694 shares

12 Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares

[]

13 Percent of Class Represented by Amount in Row (11)

0.2%

14 Type of Reporting Person

PN

Item 1. Security and Issuer.

This statement relates to shares of common stock, par value \$0.001 per share, (the "Common Stock") of Biostar Pharmaceuticals, Inc. a Maryland corporation (the "Company") having its principal executive offices at No. 588 Shiji Avenue, Xiangyang City, Shaanxi Province, The People's Republic of China..

Item 2. Identity and Background.

This Statement is filed by Godfrey2468 LP, a Delaware Limited Partnership (the "Reporting Person"), whose business address is 128 Beachside Avenue Westport, CT 06880. The Reporting Person is principally engaged in making investments.

The General Partner of the Reporting Person is Peter Godfrey, (the "General Partner"), an individual.

The Reporting Person has granted trading authorization of the shares of Common Stock to Andrew Barron Worden and shares dispositive power of the shares of Common Stock with Andrew Barron Worden.

During the last five years, to the best knowledge of the Reporting Person, neither the Reporting Person nor any

controlling person of the Reporting Person has (i) been convicted in a criminal proceeding, or (ii) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or State securities laws or finding any violation with respect to such laws.

Item 3. Source and Amount of Funds or Other Consideration.

All purchases of the Common Stock of the Company were made using working capital.

Item 4. Purpose of Transaction.

All Issuer's securities owned by the Reporting Person have been acquired by the Reporting Person for investment purposes only.

Edgar Filing: Worden Andrew Barron - Form SC 13D/A

1 Name of Reporting Person
LeeMadison9189 LP
I.R.S. Identification No. of Above Person

2 Check the Appropriate Box if a Member of a Group (a) []
(b) []

3 SEC Use Only

4 Source of Funds
WC

5 Check Box if Disclosure of Legal Proceedings is Required Pursuant to
Items 2(d) or 2(e)
[]

6 Citizenship or Place of Organization
Delaware

Number of Shares Owned By Each Reporting Person With	7	Sole Voting Power 73,498 shares
	8	Shared Voting Power 0
	9	Sole Dispositive Power 0

10 Shared Dispositive Power
73,498 shares

11 Aggregate Amount Beneficially Owned by Each Reporting Person
73,498 shares

12 Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares
[]

13 Percent of Class Represented by Amount in Row (11)
0.3%

14 Type of Reporting Person
PN

Item 1. Security and Issuer.

This statement relates to shares of common stock, par value \$0.001 per share, (the "Common Stock") of Biostar Pharmaceuticals, Inc. a Maryland corporation (the "Company") having its principal executive offices at No. 588 Shiji Avenue, Xiangyang City, Shaanxi Province, The People's Republic of China.

Item 2. Identity and Background.

This Statement is filed by LeeMadison9189 LP, a Delaware Limited Partnership (the "Reporting Person"), whose business address is 5871 East Carefree Mountain Drive Carefree, AZ 85377. The Reporting Person is principally engaged in making investments.

The General Partner of the Reporting Person is The Robert M. Mayes and Laura L. Mayes Living Trust, (the "General Partner"). Robert M. Mayes, an individual, is the Trustee for the General Partner.

The Reporting Person has granted trading authorization of the shares of Common Stock to Andrew Barron Worden and shares dispositive power of the shares of Common Stock with Andrew Barron Worden.

During the last five years, to the best knowledge of the Reporting Person, neither the Reporting Person nor any

controlling person of the Reporting Person has (i) been convicted in a criminal proceeding, or (ii) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order

Edgar Filing: Worden Andrew Barron - Form SC 13D/A

enjoining future violations of, or prohibiting or mandating activities subject to, Federal or State securities laws or finding any violation with respect to such laws.

Item 3. Source and Amount of Funds or Other Consideration.

All purchases of the Common Stock of the Company were made using working capital.

Item 4. Purpose of Transaction.

All Issuer's securities owned by the Reporting Person have been acquired by the Reporting Person for investment purposes only.

1	Name of Reporting Person		
	RossPlan LP		
	I.R.S. Identification No. of Above Person		
2	Check the Appropriate Box if a Member of a Group	(a)	[]
	(b)	[]	
3	SEC Use Only		
4	Source of Funds		
	WC		
5	Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e)		
	[]		
6	Citizenship or Place of Organization		
	Delaware		
Number of Shares Owned By Each Reporting Person With		7	Sole Voting Power
			275,826 shares
		8	Shared Voting Power
			0
		9	Sole Dispositive Power
			0
10	Shared Dispositive Power		
	275,826 shares		
11	Aggregate Amount Beneficially Owned by Each Reporting Person		
	275,826 shares		
12	Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares		
	[]		
13	Percent of Class Represented by Amount in Row (11)		
	1.1%		
14	Type of Reporting Person		
	PN		

Item 1. Security and Issuer.

This statement relates to shares of common stock, par value \$0.001 per share, (the "Common Stock") of Biostar Pharmaceuticals, Inc. a Maryland corporation (the "Company") having its principal executive offices at No. 588 Shiji Avenue, Xiangyang City, Shaanxi Province, The People's Republic of China.

Item 2. Identity and Background.

This Statement is filed by RossPlan LP, a Delaware Limited Partnership (the "Reporting Person"), whose business address is 130 E. 65th Street New York, NY 10065. The Reporting Person is principally engaged in making investments.

The General Partner of the Reporting Person is Santee River LLC, (the "General Partner"). Ross Pirastah is the managing member of the General Partner.

Edgar Filing: Worden Andrew Barron - Form SC 13D/A

The Reporting Person has granted trading authorization of the shares of Common Stock to Andrew Barron Worden and shares dispositive power of the shares of Common Stock with Andrew Barron Worden.

During the last five years, to the best knowledge of the Reporting Person, neither the Reporting Person nor any

controlling person of the Reporting Person has (i) been convicted in a criminal proceeding, or (ii) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or State securities laws or finding any violation with respect to such laws.

Item 3. Source and Amount of Funds or Other Consideration.

All purchases of the Common Stock of the Company were made using working capital.

Item 4. Purpose of Transaction.

All Issuer's securities owned by the Reporting Person have been acquired by the Reporting Person for investment purposes only.

1 Name of Reporting Person
Tibero2 LP
I.R.S. Identification No. of Above Person

2 Check the Appropriate Box if a Member of a Group (a)
(b)

3 SEC Use Only

4 Source of Funds
WC

5 Check Box if Disclosure of Legal Proceedings is Required Pursuant to
Items 2(d) or 2(e)

6 Citizenship or Place of Organization
Delaware

Number of	7	Sole Voting Power
Shares		
Owned		62,187 shares
By Each	8	Shared Voting Power
Reporting		0
Person With		
	9	Sole Dispositive Power
		0

10 Shared Dispositive Power
62,187 shares

11 Aggregate Amount Beneficially Owned by Each Reporting Person
62,187 shares

12 Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares

13 Percent of Class Represented by Amount in Row (11)
0.3%

14 Type of Reporting Person
PN

Item 1. Security and Issuer.

This statement relates to shares of common stock, par value \$0.001 per share, (the "Common Stock") of Biostar Pharmaceuticals, Inc. a Maryland corporation (the "Company") having its principal executive offices at No. 588 Shiji Avenue, Xiangyang City, Shaanxi Province, The People's Republic

Edgar Filing: Worden Andrew Barron - Form SC 13D/A

of China.

Item 2. Identity and Background.

This Statement is filed by Tiberio2 LP, a Delaware Limited Partnership (the "Reporting Person"), whose business address is 29 Evergreen Way Wokingham, Berkshire RG41 4BX United Kingdom. The Reporting Person is principally engaged in making investments.

The General Partner of the Reporting Person is Tim Robinson, (the "General Partner"), an individual.

The Reporting Person has granted trading authorization of the shares of Common Stock to Andrew Barron Worden and shares dispositive power of the shares of Common Stock with Andrew Barron Worden.

During the last five years, to the best knowledge of the Reporting Person, neither the Reporting Person nor any

controlling person of the Reporting Person has (i) been convicted in a criminal proceeding, or (ii) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or State securities laws or finding any violation with respect to such laws.

Item 3. Source and Amount of Funds or Other Consideration.

All purchases of the Common Stock of the Company were made using working capital.

Item 4. Purpose of Transaction.

All Issuer's securities owned by the Reporting Person have been acquired by the Reporting Person for investment purposes only.

1	Name of Reporting Person		
	2DanesRunnin LP		
	I.R.S. Identification No. of Above Person		
2	Check the Appropriate Box if a Member of a Group	(a) []	
	(b) []		
3	SEC Use Only		
4	Source of Funds		
	WC		
5	Check Box if Disclosure of Legal Proceedings is Required Pursuant to		
	Items 2(d) or 2(e)		
	[]		
6	Citizenship or Place of Organization		
	Delaware		
Number of	7	Sole Voting Power	
Shares			
Owned		18,253 shares	
By Each	8	Shared Voting Power	
Reporting		0	
Person With			
	9	Sole Dispositive Power	
		0	
10	Shared Dispositive Power		
	18,253 shares		
11	Aggregate Amount Beneficially Owned by Each Reporting Person		
	18,253 shares		
12	Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares		

Edgar Filing: Worden Andrew Barron - Form SC 13D/A

[]
13 Percent of Class Represented by Amount in Row (11)
0.1%
14 Type of Reporting Person
PN

Item 1. Security and Issuer.

This statement relates to shares of common stock, par value \$0.001 per share, (the "Common Stock") of Biostar Pharmaceuticals, Inc. a Maryland corporation (the "Company") having its principal executive offices at No. 588 Shiji Avenue, Xiangyang City, Shaanxi Province, The People's Republic of China.

Item 2. Identity and Background.

This Statement is filed by 2DanesRunnin LP, a Delaware Limited Partnership (the "Reporting Person"), whose business address is 5016 Silver Lake Drive Plano, TX 75093. The Reporting Person is principally engaged in making investments.

The General Partner of the Reporting Person is Higher Ground Investments, LP (the "General Partner"). The Canyons Climbing, LLC is the General Partner of Higher Ground Investments, LP. Robert A. Kaiser is the Managing Member of The Canyons Climbing, LLC.

The Reporting Person has granted trading authorization of the shares of Common Stock to Andrew Barron Worden and shares dispositive power of the shares of Common Stock with Andrew Barron Worden.

During the last five years, to the best knowledge of the Reporting Person, neither the Reporting Person nor any

controlling person of the Reporting Person has (i) been convicted in a criminal proceeding, or (ii) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or State securities laws or finding any violation with respect to such laws.

Item 3. Source and Amount of Funds or Other Consideration.

All purchases of the Common Stock of the Company were made using working capital.

Item 4. Purpose of Transaction.

All Issuer's securities owned by the Reporting Person have been acquired by the Reporting Person for investment purposes only.

1 Name of Reporting Person
JBWA2 LP
I.R.S. Identification No. of Above Person
2 Check the Appropriate Box if a Member of a Group (a) []
(b) []
3 SEC Use Only
4 Source of Funds
WC
5 Check Box if Disclosure of Legal Proceedings is Required Pursuant to
Items 2(d) or 2(e)
[]
6 Citizenship or Place of Organization
Delaware

Edgar Filing: Worden Andrew Barron - Form SC 13D/A

Number of Shares Owned	7	Sole Voting Power
By Each Reporting Person With	8	110,760 shares Shared Voting Power 0
	9	Sole Dispositive Power 0 shares
10		Shared Dispositive Power 110,760 shares
11		Aggregate Amount Beneficially Owned by Each Reporting Person 110,760 shares
12		Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares []
13		Percent of Class Represented by Amount in Row (11) 0.5%
14		Type of Reporting Person PN

Item 1. Security and Issuer.

This statement relates to shares of common stock, par value \$0.001 per share, (the "Common Stock") of Biostar Pharmaceuticals, Inc. a Maryland corporation (the "Company") having its principal executive offices at No. 588 Shiji Avenue, Xiangyang City, Shaanxi Province, The People's Republic of China.

Item 2. Identity and Background.

This Statement is filed by JBWA2 LP, a Delaware Limited Partnership (the "Reporting Person"), whose business address is 650 Bellevue Way NE Suite 3704 Bellevue, WA 98004. The Reporting Person is principally engaged in making investments.

The General Partner of the Reporting Person is Jim Jensen (the "General Partner"), an individual.

The Reporting Person has granted trading authorization of the shares of Common Stock to Andrew Barron Worden and shares dispositive power of the shares of Common Stock with Andrew Barron Worden.

During the last five years, to the best knowledge of the Reporting Person, neither the Reporting Person nor any controlling person of the Reporting Person has (i) been convicted in a criminal proceeding, or (ii) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or State securities laws or finding any violation with respect to such laws.

Item 3. Source and Amount of Funds or Other Consideration.

All purchases of the Common Stock of the Company were made using working capital.

Item 4. Purpose of Transaction.

All Issuer's securities owned by the Reporting Person have been acquired by the Reporting Person for investment purposes only.

1	Name of Reporting Person Kaufman2 LP I.R.S. Identification No. of Above Person
2	Check the Appropriate Box if a Member of a Group (a) [] (b) []

Edgar Filing: Worden Andrew Barron - Form SC 13D/A

3 SEC Use Only
4 Source of Funds
WC
5 Check Box if Disclosure of Legal Proceedings is Required Pursuant to
Items 2(d) or 2(e)
[]
6 Citizenship or Place of Organization
Delaware
Number of 7 Sole Voting Power
Shares
Owned 40,194 shares
By Each 8 Shared Voting Power
Reporting 0
Person With
9 Sole Dispositive Power
0 shares
10 Shared Dispositive Power
40,194 shares
11 Aggregate Amount Beneficially Owned by Each Reporting Person
40,194 shares
12 Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares
[]
13 Percent of Class Represented by Amount in Row (11)
0.2%
14 Type of Reporting Person
PN

Item 1. Security and Issuer.

This statement relates to shares of common stock, par value \$0.001 per share, (the "Common Stock") of Biostar Pharmaceuticals, Inc. a Maryland corporation (the "Company") having its principal executive offices at No. 588 Shiji Avenue, Xiangyang City, Shaanxi Province, The People's Republic of China.

Item 2. Identity and Background.

This Statement is filed by Kaufman2 LP, a Delaware Limited Partnership (the "Reporting Person"), whose business address is 127 W. 69th Street New York, Ny 10023. The Reporting Person is principally engaged in making investments.

The General Partner of the Reporting Person is Daniel Kaufman (the "General Partner"), an individual.

The Reporting Person has granted trading authorization of the shares of Common Stock to Andrew Barron Worden and shares dispositive power of the shares of Common Stock with Andrew Barron Worden.

During the last five years, to the best knowledge of the Reporting Person, neither the Reporting Person nor any controlling person of the Reporting Person has (i) been convicted in a criminal proceeding, or (ii) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or State securities laws or finding any violation with respect to such laws.

Item 3. Source and Amount of Funds or Other Consideration.

All purchases of the Common Stock of the Company were made using working capital.

Item 4. Purpose of Transaction.

All Issuer's securities owned by the Reporting Person have been acquired by

Edgar Filing: Worden Andrew Barron - Form SC 13D/A

the Reporting Person for investment purposes only.

1 Name of Reporting Person
Fernando Liu
I.R.S. Identification No. of Above Person

2 Check the Appropriate Box if a Member of a Group (a) []
(b) []

3 SEC Use Only

4 Source of Funds
PF

5 Check Box if Disclosure of Legal Proceedings is Required Pursuant to
Items 2(d) or 2(e)
[]

6 Citizenship or Place of Organization
People's Republic of China

Number of	7	Sole Voting Power
Shares		
Owned		3,041 shares
By Each	8	Shared Voting Power
Reporting		0
Person With		
	9	Sole Dispositive Power
		0

10 Shared Dispositive Power
3,041 shares

11 Aggregate Amount Beneficially Owned by Each Reporting Person
3,041 shares

12 Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares
[]

13 Percent of Class Represented by Amount in Row (11)
0.0%

14 Type of Reporting Person
IN

Item 1. Security and Issuer.

This statement relates to shares of common stock, par value \$0.001 per share, (the "Common Stock") of Biostar Pharmaceuticals, Inc. a Maryland corporation (the "Company") having its principal executive offices at No. 588 Shiji Avenue, Xiangyang City, Shaanxi Province, The People's Republic of China.

Item 2. Identity and Background.

This Statement is filed by Fernando Liu whose residence address is Room 302, Unit 18, 299 HuXin Road, MinHang District Shanghai 201101 China. The Reporting Person is principally employed as a Regional Manager by Barron Partners Asia whose business address is Suite 1201, Tower 1, Hyundai Plaza, 369 XianXia Road, ChangNing District, Shanghai, PRC 200336.

The Reporting Person has granted trading authorization of the shares of Common Stock to Andrew Barron Worden and shares dispositive power of the shares of Common Stock with Andrew Barron Worden.

During the last five years, to the best knowledge of the Reporting Person, neither the Reporting Person nor any controlling person of the Reporting Person has (i) been convicted in a criminal proceeding, or (ii) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or State securities laws or finding any violation with respect to such laws.

Item 3. Source and Amount of Funds or Other Consideration.

All purchases of the Common Stock of the Company were made using personal funds.

Edgar Filing: Worden Andrew Barron - Form SC 13D/A

Item 4. Purpose of Transaction.

All Issuer's securities owned by the Reporting Person have been acquired by the Reporting Person for investment purposes only.

1 Name of Reporting Person
SAS148 LP
I.R.S. Identification No. of Above Person

2 Check the Appropriate Box if a Member of a Group (a) (b)

3 SEC Use Only

4 Source of Funds
WC

5 Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e)

6 Citizenship or Place of Organization
Delaware

Number of Shares Owned By Each Reporting Person With	7	Sole Voting Power
	0	shares
	8	Shared Voting Power
	0	
	9	Sole Dispositive Power
	0	shares

10 Shared Dispositive Power
0 shares

11 Aggregate Amount Beneficially Owned by Each Reporting Person
0 shares

12 Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares

13 Percent of Class Represented by Amount in Row (11)
0.0%

14 Type of Reporting Person
PN

Item 1. Security and Issuer.

This statement relates to shares of common stock, par value \$0.001 per share, (the "Common Stock") of Biostar Pharmaceuticals, Inc. a Maryland corporation (the "Company") having its principal executive offices at No. 588 Shiji Avenue, Xiangyang City, Shaanxi Province, The People's Republic of China.

Item 2. Identity and Background.

This Statement is filed by SAS148 LP, a Delaware Limited Partnership (the "Reporting Person"), whose business address is 450 Sansome Street, 14th Floor, San Francisco, CA 94111. The Reporting Person is principally engaged in making investments.

The General Partner of the Reporting Person is Andrew Barron Worden (the "General Partner"), an individual.

During the last five years, to the best knowledge of the Reporting Person, neither the Reporting Person nor any controlling person of the Reporting Person has (i) been convicted in a criminal proceeding, or (ii) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or State securities laws or finding any violation with respect to such laws.

Edgar Filing: Worden Andrew Barron - Form SC 13D/A

Item 3. Source and Amount of Funds or Other Consideration.

All purchases of the Common Stock of the Company were made using working capital.

Item 4. Purpose of Transaction.

All Issuer's securities owned by the Reporting Person have been acquired by the Reporting Person for investment purposes only.

1 Name of Reporting Person
Olga Filippova
I.R.S. Identification No. of Above Person

2 Check the Appropriate Box if a Member of a Group (a)
(b)

3 SEC Use Only

4 Source of Funds
PF

5 Check Box if Disclosure of Legal Proceedings is Required Pursuant to
Items 2(d) or 2(e)

6 Citizenship or Place of Organization
People's Republic of China

Number of 7 Sole Voting Power
Shares
Owned 1,824 shares

By Each 8 Shared Voting Power
Reporting 0 shares
Person With

9 Sole Dispositive Power
0 shares

10 Shared Dispositive Power
1,824 shares

11 Aggregate Amount Beneficially Owned by Each Reporting Person
1,824 shares

12 Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares

13 Percent of Class Represented by Amount in Row (11)
0.0%

14 Type of Reporting Person
IN

Item 1. Security and Issuer.

This statement relates to shares of common stock, par value \$0.001 per share, (the "Common Stock") of Biostar Pharmaceuticals, Inc. a Maryland corporation (the "Company") having its principal executive offices at No. 588 Shiji Avenue, Xiangyang City, Shaanxi Province, The People's Republic of China.

Item 2. Identity and Background.

This Statement is filed by Olga Filippova whose residence address is 3 Havelock Terrace Dublin 4, Ireland. The Reporting Person is principally employed as a Principal by Barron Partners, LP whose business address is 730 Fifth Avenue, 25th floor New York, NY 10019.

The Reporting Person has granted trading authorization of the shares of Common Stock to Andrew Barron Worden and shares dispositive power of the shares of Common Stock with Andrew Barron Worden.

During the last five years, to the best knowledge of the Reporting Person, neither the Reporting Person nor any controlling person of the Reporting Person has (i) been convicted in a criminal proceeding, or (ii) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject

Edgar Filing: Worden Andrew Barron - Form SC 13D/A

to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or State securities laws or finding any violation with respect to such laws.

Item 3. Source and Amount of Funds or Other Consideration.

All purchases of the Common Stock of the Company were made using personal funds.

Item 4. Purpose of Transaction.

All Issuer's securities owned by the Reporting Person have been acquired by the Reporting Person for investment purposes only.

Item 5. Interest in Securities of the Issuer.-

There is no change to report for Item 5 except for the addition of the following:

(a) In the November 12, 2009 filing, the aggregate number of the Issuer's warrants purchased by the Reporting Persons was reported incorrectly. The correct aggregate number of warrants purchased by the Reporting Persons is 485,437.

(c) On December 16th, 2009 the Reporting Persons converted an aggregate of 1,259,090 of the Issuer's Series B Preferred Stock into 1,259,090 shares of Common Stock.

Since the last filing, the Reporting Persons sold an aggregate of 284,670 shares of the Common Stock in open market transactions at prices ranging from \$2.99 to \$3.78 per share. The Reporting Persons also converted an additional 80,150 shares of the Issuer's Series B Preferred Stock into 80,150 shares of Common Stock.

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

The Reporting Persons are filing jointly because each has severally granted trading authorization of the Issuer's shares of Common Stock to Andrew Barron Worden and therefore shares dispositive power with Andrew Barron Worden.

Item 7. Material to be Filed as Exhibits.

Not applicable.

SIGNATURE1

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: December 28, 2009

/s/ ANDREW BARRON WORDEN

Signature

Andrew Worden